ABSTRACT
Apolipoprotein M (apoM) is a novel apolipoprotein discovered in 1999 and belongs tothe lipocalin protein superfamily.The APOM gene is mainly expressed in the liver and kidney,Where it is highly regulated by transcription factors,cytokines,hormones etc.Series of studies have shown that apoM plays an important role in lipoprotein metabolism especially in high-density lipoprotein (HDL).Since the relationship between HDL and atherosclerosis (AS) has been well known,apoM is supposed to be of potential fuctional importance in AS.Here we review the progress made in understanding the characteristics of apoM and its relationship to cardiovascular disease.
ABSTRACT
With the constant change of medical electronic instruments ( MEI ) professionals' needs,the professional personnel training programs need to be adjusted and improved.Based on the analysis of the MEI professional students'employment situation,this article discusses several key issues of the personnel training program,and puts forward some suggestions of improving the MEI professional's personnel training program,in combination with the actual running in the training,the training objective,course arrangement,practice teaching etc..
ABSTRACT
Objective To evaluate the efficacy and safety of domestic olmesartan in treatment of mild to moderate essential hypertension in comparison with losartan. Methods Two hundred and thirty-seven patients with mild to moderate essential hypertension were enrolled in a randomized, double-blind, multi-center, paralleded and active-controlled trial, and were divided into olmesartan group (olmesartan 20 mg + losartan 50 mg placebo) and losartan group (losartan 50 mg + olmesartan 20 mg placebo) for a 8-week therapy. Four weeks after treatment, dosages of drugs were doubled in patients with seated diastolic blood pressure ≥90 mmHg (1 mmHg =0.133 kPa). All patients were followed up every two weeks, and the efficacy and adverse effects were observed. Another 32 patients with mild to moderate essential hypertension were enrolled and given olmesartan only, and ambulatory blood pressure monitoring was performed before and 8 weeks after treatment. Results Compared with those before treatment, both systolic blood pressure and diastolic blood pressure significantly decreased in olmesartan group and losartan group 8 weeks after treatment [(15.2 ±13.3) mmHg and (19.5 ±11.8) mmHg, respectively for systolic blood pressure (P <0.001); (15.9 ±7.48) mmHg and (16.2 ± 5.95) mmHg, respectively for diastolic blood pressure (P < 0.01) ], while there was no significant difference between these two groups (P > 0.05). There was no significant difference in total effective rate and incidence of adverse effect between these two groups (86.9% vs 93.7% and 7.63% vs 5.88% , P > 0.05) . Ambulatory blood pressure monitoring demonstrated that trough to peak ratios of systolic blood pressure and diastolic blood pressure were 86% and 71%, respectively. Conclusion Domestic olmesaratan provides an effective, safe and long action in the treatment of mild to moderate essential hypertension.
ABSTRACT
The acute therapeutic effect of enalapril,an angiotensin converting enzyme inhibitor (ACEI),in reducing blood pressure and urinary albumin excretion rate(UAER) were assessed in 32 NID- DM and 13 essential hypertensive patients.After treatment for three days,24-h blood pressure and UAER in NIDDM patients were reduced significantly.UAER of essential hypertensive patients were reduced while in hypertensive patients UAER were reduced,but blood pressure except night SBP remained unchanged. This study suggests enalapril may have a specific protect effect on kidney which is independent of the de- crease in systemic blood pressure.